FLT3 and acute myeloid leukemia: A concomitant COG phase 1 study of sorafenib in children with relapsed/refractory solid tumors or leukemias also identified tolerable dosing in children and reported complete responses in two of eight patients with FLT3–ITD AML, enabling subsequent HSCT (46).